Zostavax Approval History

• FDA approved: Yes (First approved May 25th, 2006)
• Brand name: Zostavax
• Generic name: zoster vaccine live
• Company: Merck & Co., Inc.
• Treatment for: Herpes Zoster, Prophylaxis

Zostavax (zoster vaccine live) is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

FDA Approval History for Zostavax

Date	Article
Mar 25, 2011	FDA Expands Indication for Zostavax, Merck's Shingles Vaccine, to Include Adults Ages 50 to 59
Feb 24, 2006	FDA Review Date for Merck's Investigational Shingles Vaccine Extended to May 25, 2006
Dec 15, 2005	FDA Advisory Committee Agrees that Clinical Data Support the Efficacy and Safety of Zostavax, Merck's Investigational Vaccine for Shingles, in Adults Aged 60 and Older
Jun 29, 2005	Merck Announces that FDA Has Accepted For Review Biologics License Applications for Rotateq and Zostavax
May  2, 2005	Merck Submits Biologics License Application to FDA for Zostavax, an Investigational Vaccine for Shingles and Shingles-Associated Nerve Pain

See also...

Zostavax (zoster vaccine live) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.